Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring

Renske Altena, Eric van Roon, Richard Folkeringa, Harry de Wit, Mels Hoogendoorn, Renske Altena, Eric van Roon, Richard Folkeringa, Harry de Wit, Mels Hoogendoorn

No abstract available

Keywords: interaction; novel oral anticoagulants; pulmonary embolism.

Figures

Figure 1.

Median (5th and 95th percentiles) plasma levels of rivaroxaban after oral intake of 20 mg, in patients with normal body mass index and normal renal function. Asterix indicates the plasma rivaroxaban concentration in our patient, which was measured from a blood sample taken 2 h after oral intake of 20 mg rivaroxaban. Data on median levels adapted from Mueck et al.